Mechanisms of bone invasion and metastasis in human neuroblastoma

Cancer Letters

Volumn 228, Issue 1-2, 2005, Pages 203-209

  Sohara, Yasuyoshi ^a   Shimada, Hiroyuki ^a   DeClerck, Yves A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Bone marrow mesenchymal stem cells; Bone metastasis; IL 6; Neuroblastoma

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CYTOKINE; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CELL ACTIVATION; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYELOMA; NEUROBLASTOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 23944432868     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.01.059     Document Type: Review

References (33)

1. S.G. Dubois, Y. Kalika, J.N. Lukens, G.M. Brodeur, R.C. Seeger, and J.B. Atkinson Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival J. Pediatr. Hematol. Oncol. 21 1999 181 189
2. G.D. Roodman Mechanisms of bone metastasis N. Engl. J. Med. 350 2004 1655 1664
3. K. Yoshino, M. Tanabe, N. Ohnuma, and H. Takahashi Histopathologic analysis of bone marrow and bone metastasis in murine neuroblastoma Clin. Exp. Metastasis 14 1996 459 465
4. K. Wolf, I. Mazo, H. Leung, K. Engelke, U.H. von Andrian, and E.I. Deryugina Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis J. Cell. Biol. 160 2003 267 277
5. I.J. Fidler Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis Surg. Oncol. Clin. N. Am. 10 2001 257 258
6. A. Ben Baruch Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions Breast Cancer Res. 5 2003 31 36
7. H. Geminder, O. Sagi-Assif, L. Goldberg, T. Meshel, G. Rechavi, and I.P. Witz A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma J. Immunol. 167 2001 4747 4757
8. H.V. Russell, J. Hicks, M.F. Okcu, and J.G. Nuchtern CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases J. Pediatr. Surg. 39 2004 1506 1511
9. G.A. Rodan The development and function of the skeleton and bone metastases Cancer 97 2003 726 732
10. P.J. Kostenuik, and V. Shalhoub Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption Curr. Pharm. Des. 7 2001 613 635
11. E.K. Sloan, and R.L. Anderson Genes involved in breast cancer metastasis to bone Cell. Mol. Life Sci. 59 2002 1491 1502
12. S.M. Kakonen, and G.R. Mundy Mechanisms of osteolytic bone metastases in breast carcinoma Cancer 97 2003 834 839
13. N.S. Callander, and G.D. Roodman Myeloma bone disease Semin. Hematol. 38 2001 276 285
14. P.F. Choong The molecular basis of skeletal metastases Clin. Orthop. 2003 S19 S31
15. G.D. Roodman Role of stromal-derived cytokines and growth factors in bone metastasis Cancer 97 2003 733 738
16. E.T. Keller, J. Wanagat, and W.B. Ershler Molecular and cellular biology of interleukin-6 and its receptor Front. Biosci. 1 1996 d340 d357
17. T. Michigami, M. Ihara-Watanabe, M. Yamazaki, and K. Ozono Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma Cancer Res. 61 2001 1637 1644
18. Y. Sohara, H. Shimada, M. Scadeng, H. Pollack, S. Yamada, and W. Ye Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate Cancer Res. 63 2003 3026 3031
19. D. Granchi, I. Amato, L. Battistelli, S. Avnet, S. Capaccioli, and L. Papucci In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells Int. J. Cancer 111 2004 829 838
20. Y. Sohara, H. Shimada, C. Minkin, A. Erdreich-Epstein, J.A. Nolta, Y.A. DeClerck, Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells, Cancer Res. 65 (2005) 1129 - 1135.
21. R.S. Kerbel What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Rev. 17 1998 301 304
22. C. Khanna, J.J. Jaboin, E. Drakos, M. Tsokos, and C.J. Thiele Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis In Vivo 16 2002 77 85
23. C.F. Chantrain, H. Shimada, S. Jodele, S. Groshen, W. Ye, and D.R. Shalinsky Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment Cancer Res. 64 2004 1675 1686
24. J.R. Green Antitumor effects of bisphosphonates Cancer 97 2003 840 847
25. V.B. Andela, M. Pirri, E.M. Schwarz, E.J. Puzas, R.J. O'Keefe, and J.D. Rosenblatt The mevalonate synthesis pathway as a therapeutic target in cancer Clin. Orthop. 2003 S59 S66
26. C.M. Perry, and D.P. Figgitt Zoledronic acid: a review of its use in patients with advanced cancer Drugs 64 2004 1197 1211
27. Y. Wittrant, S. Theoleyre, C. Chipoy, M. Padrines, F. Blanchard, and D. Heymann RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis Biochim. Biophys. Acta 1704 2004 49 57
28. M. Trikha, R. Corringham, B. Klein, and J.F. Rossi Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence Clin. Cancer Res. 9 2003 4653 4665
29. K.C. Anderson Moving disease biology from the lab to the clinic Cancer 97 2003 796 801
30. T. Hideshima, D. Chauhan, T. Hayashi, M. Akiyama, N. Mitsiades, and C. Mitsiades Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma Oncogene 22 2003 8386 8393
31. T. Murakami, and N. Yamamoto Roles of chemokines and chemokine receptors in HIV-1 infection Int. J. Hematol. 72 2000 412 417
32. For the AMD3100 JIV Study Group, Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune. Defic. Syndr. 37 (2004) 1253-1262.
33. S.M. Devine, N. Flomenberg, D.H. Vesole, J. Liesveld, D. Weisdorf, and K. Badel Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma J. Clin. Oncol. 22 2004 1095 1102